Ann: CHDR to conduct first-in-human phase 1 trial of IMP761, page-11

The KLH challenge triggers the immune system with a novel antigen, resulting in a quantifiable immune response that can be pharmacologically modified. Previous studies have reported that immunomodulatory agents such as cyclosporine, methotrexate, rituximab and co-stimulation blockers can modify responses driven by KLH. Doing trials on RA, Crohn’s, psoriasis etc are not only expensive and time consuming but may miss better targets such as lupus or juvenile onset diabetes.
It looks like this technology may help determine new targets for IMP761 therapy prior to trials saving time and money. It may allow comparisons to well known accepted therapies
Will this keyhole holds key to future innovations?
Sure hope so